Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in the weight-loss drug market. U.S.-listed shares fell over 5% on Monday to a four-year low around $45, continuing a downward spiral that has seen the company lose nearly…
Continue reading...